Dynamic changes in numbers and properties of circulating tumor cells and their potential applications

Cancers

Volumn 6, Issue 4, 2014, Pages 2369-2386

  Tseng, Ju Yu ^a   Yang, Chih Yung ^b   Liang, Shu Ching ^a   Liu, Ren Shyan ^a,c,d   Jiang, Jeng Kai ^d   Lin, Chi Hung ^a,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c Molecular and Genetic Imaging Core Taiwan Mouse Clinic   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e VGH Yang Ming Genome Research Center   (Taiwan)

Author keywords

Circulating tumor cells; CTC enrichment and enumeration; Metastasis

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; MAMMAGLOBIN; MUCIN 1; PERTUZUMAB; PROSTATE SPECIFIC ANTIGEN;

BIOCHIP; BREAST CANCER; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL COUNT; CIRCULATING TUMOR CELL; COLON CANCER; DRUG RESPONSE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; LUNG CANCER; METASTASIS; NON SMALL CELL LUNG CANCER; NONHUMAN; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 84935010855     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6042369     Document Type: Review

References (95)

1. Ashworth, T.R. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust. Med. J.1869, 14, 146–149.
2. Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W. et al.Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med.2004, 351, 781–791.
3. Hayes, D.F.; Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Miller, M.C.; Matera, J.; Allard, W.J.; Doyle, G.V.; Terstappen, L.W. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res.2006, 12, 4218–4224.
4. Molnar, B.; Ladanyi, A.; Tanko, L.; Sreter, L.; Tulassay, Z. Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin. Cancer Res.2001, 7, 4080–4085.
5. Cohen, S.J.; Punt, C.J.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, M.C. et al.Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol.2008, 26, 3213–3221.
6. De Bono, J.S.; Scher, H.I.; Montgomery, R.B.; Parker, C; Miller, M.C.; Tissing, H.; Doyle, G.V.; Terstappen, L.W.; Pienta, K.J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res.2008, 14, 6302-6309.
7. Krebs, M.G.; Sloane, R.; Priest, L.; Lancashire, L.; Hou, J.M.; Greystoke, A.; Ward, T.H.; Ferraldeschi, R.; Hughes, A.; Clack, G. et al.Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J. Clin. Oncol.2011, 29, 1556-1563.
8. Pantel, K.; Brakenhoff, R.H.; Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer2008, 8, 329-340.
9. Alix-Panabieres, C; Pantel, K. Challenges in circulating tumour cell research. Nat. Rev. Cancer2014, 14, 623-631.
10. Pantel, K.; Alix-Panabieres, C. The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov. 2012, 2, 974-975.
11. Hou, J.M.; Krebs, M.G; Lancashire, L.; Sloane, R.; Backen, A.; Swain, R.K.; Priest, L.J.; Greystoke, A.; Zhou, C; Morris, K. et al.Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J. Clin. Oncol.2012, 30, 525-532.
12. Rack, B.; Schindlbeck, C; Juckstock, J.; Andergassen, U.; Hepp, P.; Zwingers, T.; Friedl, T.W.; Lorenz, R.; Tesch, H.; Fasching, PA. et al.Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J. Natl. Cancer Instit. 2014, doi:10.1093/jnci/dju066.
13. Botteri, E.; Sandri, M.T.; Bagnardi, V; Munzone, E.; Zorzino, L.; Rotmensz, N.; Casadio, C; Cassatella, M.C.; Esposito, A.; Curigliano, G. et al.Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res. Treat.2010, 122, 211-217.
14. Pantel, K.; Alix-Panabieres, C; Riethdorf, S. Cancer micrometastases. Nat. Rev. Clin. Oncol.2009, 6, 339-351.
15. Fidler, I.J. The pathogenesis of cancer metastasis: The “seed and soil” hypothesis revisited. Nat. Rev. Cancer2003, 3, 453-458.
16. Valastyan, S.; Weinberg, R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell2011, 147, 275-292.
17. Gross, H.J.; Verwer, B.; Houck, D.; Hoffman, R.A.; Recktenwald, D. Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10-7. Proc. Natl. Acad. Sci. USA1995, 92, 537-541.
18. Simpson, S.J.; Vachula, M.; Kennedy, M.J.; Kaizer, H.; Coon, J.S.; Ghalie, R.; Williams, S.; van Epps, D. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp. Hematol.1995, 23, 1062-1068.
19. Ghossein, R.A.; Rosai, J.; Scher, H.I.; Seiden, M.; Zhang, Z.F.; Sun, M.; Chang, G; Berlane, K.; Krithivas, K.; Kantoff, PW. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology1997, 50, 100-105.
20. Mori, M.; Mimori, K.; Ueo, H.; Tsuji, K.; Shiraishi, T.; Barnard, G.F.; Sugimachi, K.; Akiyoshi, T. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J. Clin. Oncol.1998, 16, 128–132.
21. Ghossein, R.A.; Bhattacharya, S.; Rosai, J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin. Cancer Res.1999, 5, 1950–1960.
22. Zheng, S.; Lin, H.; Liu, J.Q.; Balic, M.; Datar, R.; Cote, R.J.; Tai, Y.C. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J. Chromatogr. A2007, 1162, 154–161.
23. Fidler, I.J.; Kripke, M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science1977, 197, 893–895.
24. Bednarz-Knoll, N.; Alix-Panabieres, C.; Pantel, K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res. 2011, 13, 228.
25. Heitzer, E.; Auer, M.; Gasch, C.; Pichler, M.; Ulz, P.; Hoffmann, E.M.; Lax, S.; Waldispuehl-Geigl, J.; Mauermann, O.; Lackner, C. et al.Complex tumor genomes inferred from single circulating tumor cells by array-cgh and next-generation sequencing. Cancer Res. 2013, 73, 2965–2975.
26. Powell, A.A.; Talasaz, A.H.; Zhang, H.; Coram, M.A.; Reddy, A.; Deng, G.; Telli, M.L.; Advani, R.H.; Carlson, R.W.; Mollick, J.A. et al.Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLOS ONE2012, 7, e33788.
27. Raimondi, C.; Gradilone, A.; Naso, G.; Vincenzi, B.; Petracca, A.; Nicolazzo, C.; Palazzo, A.; Saltarelli, R.; Spremberg, F.; Cortesi, E. et al.Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat.2011, 130, 449–455.
28. Armstrong, A.J.; Marengo, M.S.; Oltean, S.; Kemeny, G.; Bitting, R.L.; Turnbull, J.D.; Herold, C.I.; Marcom, P.K.; George, D.J.; Garcia-Blanco, M.A. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res.2011, 9, 997–1007.
29. Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M. et al.Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science2013, 339, 580–584.
30. Chao, Y.L.; Shepard, C.R.; Wells, A. Breast carcinoma cells re-express e-cadherin during mesenchymal to epithelial reverting transition. Mol. Cancer2010, 9, 179.
31. Bonnomet, A.; Syne, L.; Brysse, A.; Feyereisen, E.; Thompson, E.W.; Noel, A.; Foidart, J.M.; Birembaut, P.; Polette, M.; Gilles, C. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene2012, 31, 3741–3753.
32. Korpal, M.; Ell, B.J.; Buffa, F.M.; Ibrahim, T.; Blanco, M.A.; Celia-Terrassa, T.; Mercatali, L.; Khan, Z.; Goodarzi, H.; Hua, Y. et al.Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med.2011, 17, 1101–1108.
33. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M. et al.The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell2008, 133, 704–715.
34. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene2010, 29, 4741–4751.
35. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: An old idea—A paradigm shift. Cancer Res. 2006, doi:10.1158/0008-5472.CAN-05-3153.
36. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nature Rev. Cancer2002, 2, 442–454.
37. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S. et al.ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell2007, 1, 555–567.
38. Douville, J.; Beaulieu, R.; Balicki, D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 2009, 18, 17–25.
39. Aktas, B.; Tewes, M.; Fehm, T.; Hauch, S.; Kimmig, R.; Kasimir-Bauer, S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 2009, 11, R46.
40. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65, 10946–10951.
41. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA2003, 100, 3983–3988.
42. Dalerba, P.; Dylla, S.J.; Park, I.K.; Liu, R.; Wang, X.; Cho, R.W.; Hoey, T.; Gurney, A.; Huang, E.H.; Simeone, D.M. et al.Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA2007, 104, 10158–10163.
43. Li, M.; Zhang, B.; Zhang, Z.; Liu, X.; Qi, X.; Zhao, J.; Jiang, Y.; Zhai, H.; Ji, Y.; Luo, D. Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. BioMed Res. Int.2014, 2014, 981261.
44. Gradilone, A.; Naso, G.; Raimondi, C.; Cortesi, E.; Gandini, O.; Vincenzi, B.; Saltarelli, R.; Chiapparino, E.; Spremberg, F.; Cristofanilli, M. et al.Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization. Ann. Oncol.2011, 22, 86–92.
45. Naumov, G.N.; Townson, J.L.; MacDonald, I.C.; Wilson, S.M.; Bramwell, V.H.; Groom, A.C.; Chambers, A.F. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res. Treat.2003, 82, 199–206.
46. Demicheli, R. Tumour dormancy: Findings and hypotheses from clinical research on breast cancer. Semin. Cancer Biol.2001, 11, 297–306.
47. Aguirre-Ghiso, J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer2007, 7, 834–846.
48. Alix-Panabieres, C. EPISPOT assay: Detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res. 2012, 195, 69–76.
49. Alunni-Fabbroni, M.; Sandri, M.T. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods2010, 50, 289–297.
50. Tibbe, A.G.; Miller, M.C.; Terstappen, L.W. Statistical considerations for enumeration of circulating tumor cells. Cytometry Part A2007, 71, 154–162.
51. Trzpis, M.; McLaughlin, P.M.; de Leij, L.M.; Harmsen, M.C. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am. J. Pathol.2007, 171, 386–395.
52. Goodale, D.; Phay, C.; Brown, W.; Gray-Statchuk, L.; Furlong, P.; Lock, M.; Chin-Yee, I.; Keeney, M.; Allan, A.L. Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. Cytometry Part B Clin. Cytometry2009, 76, 107–117.
53. Goodale, D.; Phay, C.; Postenka, C.O.; Keeney, M.; Allan, A.L. Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry Part A2009, 75, 344–355.
54. Vona, G.; Sabile, A.; Louha, M.; Sitruk, V.; Romana, S.; Schutze, K.; Capron, F.; Franco, D.; Pazzagli, M.; Vekemans, M. et al.Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am. J. Pathol.2000, 156, 57–63.
55. Lin, H.K.; Zheng, S.; Williams, A.J.; Balic, M.; Groshen, S.; Scher, H.I.; Fleisher, M.; Stadler, W.; Datar, R.H.; Tai, Y.C. et al.Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin. Cancer Res.2010, 16, 5011–5018.
56. Vona, G.; Estepa, L.; Beroud, C.; Damotte, D.; Capron, F.; Nalpas, B.; Mineur, A.; Franco, D.; Lacour, B.; Pol, S. et al.Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology2004, 39, 792–797.
57. Farace, F.; Massard, C.; Vimond, N.; Drusch, F.; Jacques, N.; Billiot, F.; Laplanche, A.; Chauchereau, A.; Lacroix, L.; Planchard, D. et al.A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br. J. Cancer2011, 105, 847–853.
58. Hou, H.W.; Warkiani, M.E.; Khoo, B.L.; Li, Z.R.; Soo, R.A.; Tan, D.S.; Lim, W.T.; Han, J.; Bhagat, A.A.; Lim, C.T. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci. Rep.2013, 3, 1259.
59. Morgan, T.M.; Lange, P.H.; Vessella, R.L. Detection and characterization of circulating and disseminated prostate cancer cells. Front. Biosci.2007, 12, 3000–3009.
60. Paterlini-Brechot, P.; Benali, N.L. Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Lett. 2007, 253, 180–204.
61. Meng, S.; Tripathy, D.; Shete, S.; Ashfaq, R.; Haley, B.; Perkins, S.; Beitsch, P.; Khan, A.; Euhus, D.; Osborne, C. et al.HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. USA2004, 101, 9393–9398.
62. Aggarwal, C.; Meropol, N.J.; Punt, C.J.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.A.; Mitchell, E. et al.Relationship among circulating tumor cells, cea and overall survival in patients with metastatic colorectal cancer. Ann. Oncol.2013, 24, 420–428.
63. Witzig, T.E.; Bossy, B.; Kimlinger, T.; Roche, P.C.; Ingle, J.N.; Grant, C.; Donohue, J.; Suman, V.J.; Harrington, D.; Torre-Bueno, J. et al.Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin. Cancer Res.2002, 8, 1085–1091.
64. Talasaz, A.H.; Powell, A.A.; Huber, D.E.; Berbee, J.G.; Roh, K.H.; Yu, W.; Xiao, W.; Davis, M.M.; Pease, R.F.; Mindrinos, M.N. et al.Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc. Natl. Acad. Sci. USA2009, 106, 3970–3975.
65. Nagrath, S.; Sequist, L.V.; Maheswaran, S.; Bell, D.W.; Irimia, D.; Ulkus, L.; Smith, M.R.; Kwak, E.L.; Digumarthy, S.; Muzikansky, A. et al.Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature2007, 450, 1235–1239.
66. Karabacak, N.M.; Spuhler, P.S.; Fachin, F.; Lim, E.J.; Pai, V.; Ozkumur, E.; Martel, J.M.; Kojic, N.; Smith, K.; Chen, P.I. et al.Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat. Protoc.2014, 9, 694–710.
67. Mejean, A.; Vona, G.; Nalpas, B.; Damotte, D.; Brousse, N.; Chretien, Y.; Dufour, B.; Lacour, B.; Brechot, C.; Paterlini-Brechot, P. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J. Urol.2000, 163, 2022–2029.
68. Zach, O.; Kasparu, H.; Krieger, O.; Hehenwarter, W.; Girschikofsky, M.; Lutz, D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mrna. J. Clin. Oncol.1999, 17, 2015–2019.
69. De Cremoux, P.; Extra, J.M.; Denis, M.G.; Pierga, J.Y.; Bourstyn, E.; Nos, C.; Clough, K.B.; Boudou, E.; Martin, E.C.; Muller, A. et al.Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin. Cancer Res.2000, 6, 3117–3122.
70. Hauch, S.; Zimmermann, S.; Lankiewicz, S.; Zieglschmid, V.; Bocher, O.; Albert, W.H. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res. 2007, 27, 1337–1341.
71. Gerges, N.; Rak, J.; Jabado, N. New technologies for the detection of circulating tumour cells. Br. Med. Bull.2010, 94, 49–64.
72. Rao, C.G.; Chianese, D.; Doyle, G.V.; Miller, M.C.; Russell, T.; Sanders, R.A., Jr.; Terstappen, L.W. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int. J. Oncol.2005, 27, 49–57.
73. Lacroix, M. Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer2006, 13, 1033–1067.
74. Pachmann, K.; Camara, O.; Kavallaris, A.; Krauspe, S.; Malarski, N.; Gajda, M.; Kroll, T.; Jorke, C.; Hammer, U.; Altendorf-Hofmann, A. et al.Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J. Clin. Oncol.2008, 26, 1208–1215.
75. Yu, M.; Stott, S.; Toner, M.; Maheswaran, S.; Haber, D.A. Circulating tumor cells: Approaches to isolation and characterization. J. Cell Biol.2011, 192, 373–382.
76. Hristozova, T.; Konschak, R.; Budach, V.; Tinhofer, I. A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers. Cytometry Part A2012, 81, 489–495.
77. Rosenblatt, J.I.; Hokanson, J.A.; McLaughlin, S.R.; Leary, J.F. Theoretical basis for sampling statistics useful for detecting and isolating rare cells using flow cytometry and cell sorting. Cytometry1997, 27, 233–238.
78. Allan, A.L.; Keeney, M. Circulating tumor cell analysis: Technical and statistical considerations for application to the clinic. J. Oncol. 2010, 2010, 426218.
79. Racila, E.; Euhus, D.; Weiss, A.J.; Rao, C.; McConnell, J.; Terstappen, L.W.; Uhr, J.W. Detection and characterization of carcinoma cells in the blood. Proc. Natl. Acad. Sci. USA1998, 95, 4589–4594.
80. Uhr, J.W. The clinical potential of circulating tumor cells; the need to incorporate a modern “immunological cocktail” in the assay. Cancers2013, 5, 1739–1747.
81. Thalgott, M.; Rack, B.; Maurer, T.; Souvatzoglou, M.; Eiber, M.; Kress, V.; Heck, M.M.; Andergassen, U.; Nawroth, R.; Gschwend, J.E. et al.Detection of circulating tumor cells in different stages of prostate cancer. J. Cancer Res. Clin. Oncol.2013, 139, 755–763.
82. Franken, B.; de Groot, M.R.; Mastboom, W.J.; Vermes, I.; van der Palen, J.; Tibbe, A.G.; Terstappen, L.W. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012, 14, R133.
83. Rahbari, N.N.; Bork, U.; Kircher, A.; Nimitz, T.; Scholch, S.; Kahlert, C.; Schmidt, T.; Steinert, G.; Ulrich, A.B.; Reissfelder, C. et al.Compartmental differences of circulating tumor cells in colorectal cancer. Ann. Surg. Oncol.2012, 19, 2195–2202.
84. Tseng, J.Y.; Yang, C.Y.; Liang, S.C.; Liu, R.S.; Yang, S.H.; Lin, J.K.; Chen, Y.M.; Wu, Y.C.; Jiang, J.K.; Lin, C.H. Interleukin-17A modulates circulating tumor cells in tumor draining vein of colorectal cancers and affects metastases. Clin. Cancer Res.2014, 20, 2885–2897.
85. Fehm, T.; Hoffmann, O.; Aktas, B.; Becker, S.; Solomayer, E.F.; Wallwiener, D.; Kimmig, R.; Kasimir-Bauer, S. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009, 11, R59.
86. Stathopoulou, A.; Vlachonikolis, I.; Mavroudis, D.; Perraki, M.; Kouroussis, C.; Apostolaki, S.; Malamos, N.; Kakolyris, S.; Kotsakis, A.; Xenidis, N. et al.Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J. Clin. Oncol.2002, 20, 3404–3412.
87. Stathopoulou, A.; Ntoulia, M.; Perraki, M.; Apostolaki, S.; Mavroudis, D.; Malamos, N.; Georgoulias, V.; Lianidou, E.S. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int. J. Cancer.2006, 119, 1654–1659.
88. Allen-Mersh, T.G.; McCullough, T.K.; Patel, H.; Wharton, R.Q.; Glover, C.; Jonas, S.K. Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br. J. Surg.2007, 94, 96–105.
89. Bauernhofer, T.; Zenahlik, S.; Hofmann, G.; Balic, M.; Resel, M.; Pirchmoser, R.; Regitnig, P.; Ambros, P.; Dandachi, N.; Samonigg, H. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncol. Rep.2005, 13, 179–184.
90. Bidard, F.C.; Fehm, T.; Ignatiadis, M.; Smerage, J.B.; Alix-Panabieres, C.; Janni, W.; Messina, C.; Paoletti, C.; Muller, V.; Hayes, D.F. et al.Clinical application of circulating tumor cells in breast cancer: Overview of the current interventional trials. Cancer Metastasis Rev. 2013, 32, 179–188.
91. Punnoose, E.A.; Atwal, S.; Liu, W.; Raja, R.; Fine, B.M.; Hughes, B.G.; Hicks, R.J.; Hampton, G.M.; Amler, L.C.; Pirzkall, A. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res.2012, 18, 2391–2401.
92. Reid, A.H.; Attard, G.; Danila, D.C.; Oommen, N.B.; Olmos, D.; Fong, P.C.; Molife, L.R.; Hunt, J.; Messiou, C.; Parker, C. et al.Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol.2010, 28, 1489–1495.
93. Danila, D.C.; Morris, M.J.; de Bono, J.S.; Ryan, C.J.; Denmeade, S.R.; Smith, M.R.; Taplin, M.E.; Bubley, G.J.; Kheoh, T.; Haqq, C. et al.Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol.2010, 28, 1496–1501.
94. De Bono, J.S.; Logothetis, C.J.; Molina, A.; Fizazi, K.; North, S.; Chu, L.; Chi, K.N.; Jones, R.J.; Goodman, O.B., Jr.; Saad, F. et al.Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med.2011, 364, 1995–2005.
95. Smerage, J.B.; Barlow, W.E.; Hortobagyi, G.N.; Winer, E.P.; Leyland-Jones, B.; Srkalovic, G.; Tejwani, S.; Schott, A.F.; O’Rourke, M.A.; Lew, D.L. et al.Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J. Clin. Oncol.2014, 32, 3483–3489.